Phase III trial to evaluate the efficacy of neoadjuvant chemotherapy with S-1 plus oxaliplatin followed by D2 gastrectomy with adjuvant S-1 in locally advanced gastric cancer.(JCOG1509, NAGISA trial)
Phase 3
Recruiting
- Conditions
- Gastric cancer
- Registration Number
- JPRN-UMIN000024065
- Lead Sponsor
- Japan Clinical Oncology Group (JCOG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 470
Inclusion Criteria
Not provided
Exclusion Criteria
1) Synchronous or metachronous (within 5 years) malignancies. 2) Infectious disease requiring systemic treatment. 3) Body temperature of 38 degrees Celsius or higher. 4) During pregnancy, within 28 days of postparturition, or during lactation. 5) Severe mental disease. 6) Receiving continuous systemic corticosteroid or immunosuppressant treatment. 7) Under treatment with flucytosine, phenytoin, or warfarin. 8) History of unstable angina pectoris within three weeks or myocardial infarction within six months before registration. 9) Poorly controlled diabetes. 10) Interstitial pneumonia, pulmonary fibrosis, or severe emphysema based on chest CT.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method